These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20889007)

  • 1. [Recent advances in Saccharomyces boulardii research].
    Im E; Pothoulakis C
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S62-70. PubMed ID: 20889007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.
    Pothoulakis C
    Aliment Pharmacol Ther; 2009 Oct; 30(8):826-33. PubMed ID: 19706150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: yeast as probiotics -- Saccharomyces boulardii.
    Czerucka D; Piche T; Rampal P
    Aliment Pharmacol Ther; 2007 Sep; 26(6):767-78. PubMed ID: 17767461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes.
    Dalmasso G; Cottrez F; Imbert V; Lagadec P; Peyron JF; Rampal P; Czerucka D; Groux H; Foussat A; Brun V
    Gastroenterology; 2006 Dec; 131(6):1812-25. PubMed ID: 17087945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
    Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
    Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis.
    Chen X; Kokkotou EG; Mustafa N; Bhaskar KR; Sougioultzis S; O'Brien M; Pothoulakis C; Kelly CP
    J Biol Chem; 2006 Aug; 281(34):24449-54. PubMed ID: 16816386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saccharomyces boulardii in childhood.
    Vandenplas Y; Brunser O; Szajewska H
    Eur J Pediatr; 2009 Mar; 168(3):253-65. PubMed ID: 19096876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
    Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
    Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis.
    Lee SK; Kim YW; Chi SG; Joo YS; Kim HJ
    Dig Dis Sci; 2009 Feb; 54(2):255-63. PubMed ID: 18612822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic.
    Justino PFC; Franco AX; Pontier-Bres R; Monteiro CES; Barbosa ALR; Souza MHLP; Czerucka D; Soares PMG
    Cytokine; 2020 Jan; 125():154791. PubMed ID: 31401369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Saccharomyces boulardii CNCM I-745 - the medicinal yeast improves intestinal enzyme function].
    Moré MI
    MMW Fortschr Med; 2019 Mar; 161(Suppl 4):20-24. PubMed ID: 30895510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversity of
    Czerucka D; Rampal P
    World J Gastroenterol; 2019 May; 25(18):2188-2203. PubMed ID: 31143070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review.
    Tung JM; Dolovich LR; Lee CH
    Can J Gastroenterol; 2009 Dec; 23(12):817-21. PubMed ID: 20011734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells].
    Lee SK; Kim HJ; Chi SG; Jang JY; Nam KD; Kim NH; Joo KR; Dong SH; Kim BH; Chang YW; Lee JI; Chang R
    Korean J Gastroenterol; 2005 May; 45(5):328-34. PubMed ID: 15908765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial.
    Pozzoni P; Riva A; Bellatorre AG; Amigoni M; Redaelli E; Ronchetti A; Stefani M; Tironi R; Molteni EE; Conte D; Casazza G; Colli A
    Am J Gastroenterol; 2012 Jun; 107(6):922-31. PubMed ID: 22472744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system].
    Stier H; Bischoff SC
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):1-6. PubMed ID: 28643294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients.
    Lewis SJ; Potts LF; Barry RE
    J Infect; 1998 Mar; 36(2):171-4. PubMed ID: 9570649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.
    Qamar A; Aboudola S; Warny M; Michetti P; Pothoulakis C; LaMont JT; Kelly CP
    Infect Immun; 2001 Apr; 69(4):2762-5. PubMed ID: 11254650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saccharomyces boulardii CNCM I-745 in different clinical conditions.
    Dinleyici EC; Kara A; Ozen M; Vandenplas Y
    Expert Opin Biol Ther; 2014 Nov; 14(11):1593-609. PubMed ID: 24995675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea.
    Swidsinski A; Loening-Baucke V; Verstraelen H; Osowska S; Doerffel Y
    Gastroenterology; 2008 Aug; 135(2):568-79. PubMed ID: 18570896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.